Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose,and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate(ADC), in Participants with Advanced HER2+ Solid Tumors'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National Cancer Centre
Tan Tock Seng Hospital
Trial Status: Ongoing, Recruiting
Principal Investigator(s):
Dr Tan Jing Ying Tira
Dr Valerie Heong Yue Ming
Published by HT Digital Content Services with permission from Health Daily Digest....